Daily Round Up 7/8/15: ETE, ATLS, LAYN, LAWS

by: InsiderInsights


Tables of the top insider purchases and sales filed with the SEC on 7/8/15, based on dollar value.

Dollar values often do not equate with significance when it comes to insider trades.

Proprietary Insider Company Ratings are relayed to clarify significance.

Dollar value is only one metric to assess the significance of an insider transaction, but when high dollar value intersects with significance it spotlights a stock investors should take the time to consider. InsiderInsights Daily Round Up articles are intended as initial research tools, so investors can separate real insider investment intelligence from time-wasting noise.

Click the Company Name links in the tables below to analyze a company's or insider's full insider history. Also feel free to email us with any questions on our proprietary insider data, Insider Filer Statistics, and Insider Company Ratings.

Educational note from InsiderInsights:
Insider filing volumes are at a seasonal low point due to companies closing trading windows to their insiders until quarterly earnings are released. As a result, the dollar values of trades featured in our Daily round Up articles (particularly the purchases) will likely be lower than usual until early August.

On Today's Tables:

Insider trades were rated Nearly Significant at:

  • Lawson Products (NASDAQ:LAWS);
  • Layne Christensen (NASDAQ:LAYN);
  • Energy Transfer Equity (NYSE:ETE), and;
  • Atlas Energy Group (NYSE:ATLS).

Insider trades were considered Insignificant at:

  • Rokwader (OTCPK:ROKR);
  • New Media Investment (NYSE:NEWM);
  • Calamos Asset (NASDAQ:CLMS);
  • Calamos Dynamic Convertible & Income Fund (NASDAQ:CCD);
  • Oncosec Medical (NASDAQ:ONCS);
  • Facebook (NASDAQ:FB);
  • Stryker (NYSE:SYK);
  • Eplus (NASDAQ:PLUS);
  • Lyondellbasell Ind (NYSE:LYB);
  • Lgi Homes (NASDAQ:LGIH);
  • Jazz Pharm (NASDAQ:JAZZ);
  • Illumina (NASDAQ:ILMN);
  • Hff (NYSE:HF), and;
  • Antares Pharma (NASDAQ:ATRS).

There is a Conflicted Insider Signal (both purchases & sales) at:

  • Capella Education (NASDAQ:CPLA).

There is an IPO at:

  • Pieris Pharm (NASDAQ:PIRS).

It's difficult to argue significance for most transactions made during IPOs.

Insider Purchases
#: Filer Name Insider Titles Company Name Ticker Trans
Dollar Value
1 Warren Kelcy L DIR,BO Energy Trans Eq ETE B $63,042,796
2 Coco Partners BO Rokwader ROKR JB* $3,050,000
3 Cooperman Leon BO New Media Inv NEWM B $2,051,916
4 Orbimed Advisors DIR,BO Pieris Pharm PIRS JB* $1,375,000
5 King Luther Capital Mgt BO Lawson Products LAWS B $977,760
6 Slansky Richard B CFO Oncosec Medical ONCS JB* $918,000
7 Calamos John P CB,CEO,BO Calamos Asset CLMS B $446,382
8 Cooperman Leon BO Atlas Energy Group ATLS B $394,200
9 Obus Nelson DIR Layne Christensen LAYN B $304,618
10 Calamos John P CB,PR,DIR Calamos Dyn Conv & Inc Fd CCD B $249,904

Source: | Key to Insider Title and Trans Type Codes :
B =Open-market Buy; AB=10b5-1 (automatic) Buy; JB*=Buy indicated as being open-market, but not confirmed by trading price range and volume for the session.

Insider Sales
#: Filer Name Insider Titles Company Name Ticker Trans
Dollar Value
1 Shank Stephen G DIR Capella Education CPLA AS $2,830,517
2 Walt David R DIR Illumina ILMN AS $2,642,507
3 Brown Kevin W VP Lyondellbasell Ind LYB AS $2,410,815
4 Enright Patrick G DIR Jazz Pharm JAZZ AS $1,771,055
5 Flynn James E BO Antares Pharma ATRS S $1,733,354
6 Norton Phillip G CEO,DIR Eplus PLUS AS $1,703,416
7 Cox Christopher O Facebook FB AS $1,340,595
8 Lipar Thomas E BO Lgi Homes LGIH AS $1,309,556
9 Thornton Joe Jr PR,DIR Hff HF AS $1,278,855
10 Stryker Ronda E DIR Stryker SYK AS $1,147,312 | Key to Insider Title and Trans Type Codes :
S =Open-market Sale; AS=10b5-1 (automatic) Sale; JS*=Sale indicated as being open-market, but not confirmed by trading price range and volume for the session.

If you're interested in the insider history of a stock not shown here, you can search by ticker.

Did you miss our Previous Daily Round Up?

Disclosure: I/we have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours.

I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Editor's Note: This article covers one or more stocks trading at less than $1 per share and/or with less than a $100 million market cap. Please be aware of the risks associated with these stocks.

About this article:

Author payment: $35 + $0.01/page view. Authors of PRO articles receive a minimum guaranteed payment of $150-500.
Want to share your opinion on this article? Add a comment.
Disagree with this article? .
To report a factual error in this article, click here